Obagi Is Now Making Fillers: What Saypha MagIQ and ChIQ Mean for Med Spa Clients

A well-known skincare name just became a filler brand. Here is what the newly approved Obagi saypha MagIQ and ChIQ injectables are, what they are cleared for, and what it means if you are weighing a filler appointment in Las Vegas.

A Skincare Name Becomes a Filler Brand

For years, the Obagi name has meant medical-grade skincare lines sold through licensed practices rather than needles. That changed when Obagi Medical, owned by the consumer beauty company Waldencast, moved into injectables with a hyaluronic acid filler called saypha MagIQ, followed this summer by a second product, saypha ChIQ. Both are manufactured by the Austrian company Croma-Pharma, which has sold versions of these gels in Europe for years, and both are now cleared for use in the United States under the Obagi Medical brand.

It is a notable shift for the med spa world because it puts a recognizable skincare company directly into the same aisle as Restylane, Juvederm, and RHA. For clients, the practical question is not which brand name is on the box, it is what the product is approved to do and whether a treatment fits your goals, which is always a conversation to have with a licensed injector rather than a decision to make from a headline.

Two Products, Two Different Jobs

Saypha MagIQ was the first of the pair to clear FDA review, with approval supported by a US clinical study that followed 270 patients for 48 weeks and was built around treating nasolabial folds, the creases that run from the nose to the corners of the mouth. That trial reported that the filler performed comparably to an existing approved filler on safety and results measures.

Saypha ChIQ followed with its own clearance in mid-June for a different job: cheek augmentation and correcting midface contour deficiencies in adults over 21. Because it is formulated as a higher-lift gel, it is positioned more for structural support and volume in the cheek area than for softening a fold or line. Having two products with different jobs lets a provider match the gel to the specific area being treated instead of using one formulation for everything.

The Technology Obagi Is Marketing Behind the Gel

Both products use what Croma-Pharma calls MACRO Core Technology, described as a manufacturing process meant to create a more stable, evenly distributed hyaluronic acid gel with a predictable injection feel and swelling pattern. Manufacturers make similar claims about consistency across most modern filler lines, so this is a feature to ask a provider about directly rather than something to take at face value from marketing copy.

One oculoplastic surgeon quoted in trade coverage of the ChIQ approval described it as filling an important gap, calling it a higher G-prime gel built for structural lift. That kind of framing is useful context, but it is not a promise of a particular result for any individual client, since outcomes depend on anatomy, technique, and how a person's skin responds.

What Early Real-World Feedback Looks Like

Because these are brand new to the US market, Obagi Medical set up a large post-launch monitoring effort called the ALOHA Program to track how injectors and practices are actually using the products in real clinics rather than only in a controlled trial setting. Interim figures released from that program show that the large majority of participating injectors see MagIQ as a useful addition alongside the filler options they already offer, rather than a replacement for everything in their kit.

The same interim data also pointed to a meaningful share of participating practices going on to look at other Obagi skincare products after adopting the filler, a notch above what the company frames as a typical industry rate. Early program data like this is worth knowing about, but it reflects provider sentiment in the first months of a launch, not a long-term track record, which only builds over time as more patients are treated.

What This Means If You Are Considering a Filler in Las Vegas

A new filler brand entering the market is not, by itself, a reason to change your treatment plans. What matters more is whether a specific product is a good fit for the area you want addressed, and whether your provider is licensed and experienced with it. If you already have a filler you like, there is no need to switch simply because a new option launched.

If you are curious whether saypha MagIQ, saypha ChIQ, or another established filler makes the most sense for your face and goals, that is exactly the kind of question worth bringing to a consult. Book a consult with our team at Med Spa Las Vegas and we can talk through the options honestly, with no pressure and no promises beyond a straightforward conversation about what a treatment can realistically offer.

6 Things to Know About the New Obagi Filler Line

Here is a quick rundown of what makes saypha MagIQ and ChIQ different from the fillers you may already be familiar with, and what questions are worth asking before booking either one.

1. Two products, two indications: MagIQ is cleared for nasolabial folds, while ChIQ is cleared for cheek and midface contour correction in patients over 21.
2. Made by Croma-Pharma: Both gels are manufactured by the Austrian company Croma-Pharma and sold in the US under the Obagi Medical brand.
3. A newer entrant, not an unknown one: Versions of these gels have a longer history in European markets before reaching US clearance.
4. Only offered through licensed providers: Like other prescription-grade fillers, these products are meant to be administered only by trained, licensed injectors.
5. Different lift profiles: ChIQ is formulated as a firmer, higher-lift gel for structure, while MagIQ is built more for softening lines and folds.
6. Still building a track record: Real-world data is still early, so ask any provider how much hands-on experience they have with the specific product.

← More from the Med Spa Las Vegas blog